Introduction
Initially, cardiac viral infections were documented in the clinical context of acute myocarditis. Coxsackievirus B3 (CoxB3) was the first virus detected in this condition in humans, 1 and adenoviruses of serotypes 2 and 5 were later described as common agents of myocarditis in children. 2 Systematic screening of patients with dilated cardiomyopathy has recently revealed that a rather broad spectrum of viruses may also chronically persist in human myocardium. 3 It is therefore assumed that acute cardiac viral infections may cause not only acute illness, but also chronic heart disease if not definitely eliminated from the heart. 4 The disease may progress to terminal heart failure and then require heart transplantation as a last therapeutic option.
RNA interference (RNAi) is a process of posttranscriptional gene silencing mediated by double-stranded RNA (dsRNA). The introduction of double-stranded small interfering RNAs (siRNA) or vectors expressing short hairpin RNA (shRNA) has already been successfully used to inhibit the replication of multiple viruses in vitro and in vivo including respiratory viruses, 5 hepatitis B 6, 7 and C viruses, 8 foot-and-mouth disease virus, 9 human herpesvirus-6, 10 cytomegalovirus, 11 SARS coronarvirus, 12 HIV-1 13 and CoxB3. 14, 15 However, the efficiency of RNAi depends on exact homology of the siRNA to the target sequence. A single mismatch can be sufficient to abrogate silencing by RNAi. 16 Many RNA viruses encode polymerase enzymes that lack proofreading abilities and, as a result, have high mutation rates. Thus, there is a high probability that viruses will rapidly develop resistance to a particular siRNA during virus replication by incorporation of nucleotide mutations within the target sequence of the siRNA. Thus, it has been shown that hepatitis C virus becomes resistant against a particular siRNA after several cycles of replication by the incorporation of point mutations within the siRNA target sequence. 17 Similar data have been reported for HIV-1 18 and poliovirus infections. 19 Therefore, therapeutic targeting of nonvariable virus-binding receptors on susceptible cells or other host cell molecules directly or indirectly involved in virus infections is an interesting alternative to targeting of the virus itself. 15, [20] [21] [22] [23] [24] [25] One approach of this type showed that downregulation of the CD4-independent attachment receptor (DC-SIGN) significantly inhibited HIV infection of dendritic cells (DC) and prevented the transfer of infectious HIV-1 particles from DC to T cells. 22 Adenoviruses of types 2 and 5 and CoxB3 use the coxsackievirus-adenovirus-receptor (CAR) to infect their target cells, either for virus attachment (adenoviruses) or virus internalization (CoxB3). 26 Therefore, CAR represents an attractive target for the inhibition of cardiac CoxB3 and adenovirus infections. It has been shown recently that suppression of CAR by RNAi results in inhibition of CoxB3 infections. 15, 27 These studies were carried out with cells of non-cardiac origin, and chemically synthesized siRNAs were used to inhibit CAR expression. However, the therapeutic use of synthetic siRNAs is significantly limited by their rapid degradation in target cells resulting in only transient gene silencing. 28 Moreover, most cells of cardiac origin are very difficult to transfect with chemically synthesized siRNAs even in vitro. These problems are significantly aggravated in vivo. Despite intense efforts during recent years, systemic and target organ-specific delivery of siRNAs remains a major hurdle for in vivo applications of RNAi.
Therefore, we investigated the antiviral potential of CAR gene silencing in cells of cardiac origin by use of newly developed adenoviral vectors (AdVs) that generate shRNA against murine or rat CAR (shCAR).
shCAR treatment of HL-1 cells and primary neonatal rat cardiomyocytes (PNCMs) led to almost complete silencing of CAR gene expression and efficient inhibition of CoxB3 infection in both cell types, whereas efficient inhibition of adenovirus infections was observed only in the primary cells. The studies thus indicate cell typespecific responses of cellular CAR to shCAR treatment, which need to be considered as important determinants of this new antiviral approach in vivo.
Results

Selection and specificity of mouse CAR shRNAs
To investigate the efficacy of CAR silencing for the inhibition of adenovirus and CoxB3 infection in cardiac HL-1 cells, we generated a total of three shRNAs (shCAR2 m , shCAR3 m , shCAR4 m ) directed against the extracellular domains of the mCAR splice variants mCAR-1 26 and mCAR-2 29 ( Figure 1 ) following published siRNA selection criteria. 30 DNA oligonucleotides encoding these shRNAs were then cloned into expression plasmids under the control of a murine RNA polymerase III U6 promotor. To test their efficacies, we co-transfected 293T cells with shCAR2 m -, shCAR3 m -or shCAR4 mexpressing plasmid, together with plasmids expressing recombinant mCAR1 and mCAR2. As a transfection control, a plasmid expressing an irrelevant shRNA was used. To determine the extent of recombinant mCAR1-and mCAR2-mRNA downregulation, total cellular RNA was isolated 48 h after transfection and Northern blot hybridization was carried out. These experiments showed that two shRNAs were highly efficient: shCAR2 m with 93% silencing and shCAR4 m with 97% silencing of mCAR1-and mCAR2-mRNA. The control To analyze the specificities of shCAR2 m and shCAR4 m , both were also tested for downregulation of human CAR (hCAR) by co-transfection with a plasmid expressing recombinant soluble hCAR. None of the mouse CARspecific shRNAs influenced hCAR-mRNA expression. In contrast, a human-specific shRNA efficiently silenced hCAR-mRNA expression (Figure 2b ). Considering that shCAR2 m has only one mismatch and shCAR4 m three mismatches as compared to hCAR-mRNA, these experiments indicate very high species specificity of the selected mCAR-shRNAs.
Silencing of mCAR in mouse cardiac HL-1 cells
To determine the optimal AdV dose for transduction of mouse cardiac HL-1 cells, we first transduced HL-1 cells with a GFP-expressing marker AdV at a multiplicity of infection (MOI) from 5 to 1000. At an MOI from 60 to 100, GFP expression was seen in 76-80% of the cells, whereas no cytotoxic effects were observed. Further dose escalation resulted in an only slight further increase of transduction rate (Figure 3a) , and at an MOI of 500 or higher, cytotoxic effects became evident (increase of apoptotic cells, reduction of cell growth). HL-1 cells express mCAR1 but no mCAR2 on their cell surface (not shown). Therefore, the silencing capacity of the new AdshCAR4 m (Figure 1) , which expresses the aboveevaluated most efficient shCAR4 m , was investigated with respect to mCAR1 expression in HL-1 cells only. To assess the amount of AdV-generated shCAR4 m , HL-1 cells were transduced with AdshCAR4 m at an MOI from 5 to 1000. The expression of shCAR4 m was analyzed 24, 48 and 72 h later. A time-and dose-dependent transcription of shCAR4 m was detected ( Figure 3b) . As a consequence of shRNA expression, strong downregulation of mCAR1-mRNA was observed 48 and 72 h after transduction. Near maximal reduction of 85-90% was observed at an MOI of 100. Higher doses did not result in Figure 3c ). These results indicate that an MOI of 100 was optimal for HL-1 transduction, as this dose allowed strong downregulation of mCAR1-mRNA in HL-1 cells, although cytotoxicity of the viral vector was still very low. We next investigated mCAR1 protein expression after transduction of HL-1 cells with AdshCAR4 m at an MOI of 100. To disrupt pre-existing membrane-associated mCAR1, HL-1 cells were trypsinized 24 h after AdshCAR4 m transduction and then re-seeded. This procedure led to ablation of mCAR1 protein at the cell surface 2 days after transduction (Figure 4a and b) . In contrast, control cells rapidly re-expressed mCAR1 (Figure 4b ). Two days after AdshCAR4 m treatment, a few cells still displayed some membrane-associated mCAR1 immunoreactivity (Figure 4b ), probably reflecting residual mCAR1 domains still anchored in the cell membrane after trypsinization. At days 3 and 4 after AdshCAR4 m transduction, mCAR1 immunoreactivity disappeared from HL-1 cells, whereas it remained permanently detectable in the control cells ( Figure 4b ). Interestingly, CAR was expressed only at cell-to-cell contact sites in HL-1 cells, suggesting that the observed stability of CAR in intact monolayers is determined by homophilic or heterophilic CAR interaction at cell-to-cell contact sites. Together, the results indicate that AdshCAR4 m treatment efficiently inhibits the de novo synthesis of mCAR1.
Inhibition of CoxB3 replication in HL-1 cells by AdshCAR4 m
The antiviral effect of mCAR1 silencing was now investigated with respect to CoxB3 for which cellular CAR constitutes the internalization receptor. For this purpose, we first investigated the CoxB3 protective efficacy of AdshCAR4 m as a function of dose, at an MOI of AdshCAR4 m ranging from 10 to 100, using the same trypsin-involving experimental procedure as described above. HL-1 cells were infected with CoxB3 48 h after transduction with AdshCAR4 m and the amount of newly generated progeny virus was determined 6 days later. Virus plaque assays clearly demonstrated that CoxB3 replicates in HL-1 cells, but at a rather low frequency because no cytopathogenic effect was visible during the 6-day investigation period. As expected, the strongest reduction of CoxB3 progeny virus production by 97% was observed at the highest AdshCAR4 m dose Cells were then trypsinized, re-seeded and investigated using the polyclonal rabbit anti-CAR antibody H-300 directed against the extracellular domain of CAR. mCAR1 protein became undetectable as early as 2 days after transduction with AdshCAR4 m , whereas in the controls mCAR1 protein was abundantly expressed. (b) Detection of mCAR1 knockdown by indirect immunofluorescence. HL-1 cells were treated as in (a). mCAR1 expression was detected by indirect immunofluorescence using the polyclonal rabbit antibody RP-291 56 directed against the CAR variant with intracellular SIV tail (mCAR variant 1, accession no. NM_001025192). mCAR1 was abundantly expressed over the whole investigation period (4 days after transduction) in HL-1 cells transduced with control vector (left-hand panels). In contrast, mCAR1 was visible at low levels 2 days after transduction but became undetectable at later time points (right-hand panels). Cell nuclei are stained with 4,6-diamidino-2-phenylindole and overlaid images are shown. Notably, mCAR1 was localized only at cell-cell contact sites (white arrows), whereas cell membrane regions not in contact with other cells displayed no mCAR1 protein (yellow arrows). mCAR2 expression was not detectable in HL-1 cells by using polyclonal rabbit antibody 56 directed against the CAR variant with intracellular TVV tail (mCAR variant 2, accession no. NM_009988) (not shown). We later noted that CAR protein was downregulated by AdshCAR4 with similar kinetics if the trypsinization and re-seeding step was omitted. Figures 5b and 6 show that also the virus-related functionality of CAR in HL-1 cells was abandoned irrespective of trypsinization.
Antiviral efficacy of CAR silencing by RNA interference H Fechner et al with an MOI of 100. Nevertheless, MOIs of 50 and 25 still led to significant inhibition of CoxB3 replication by 85 and 75%, respectively, whereas an MOI of 10 showed no significant effect (Figure 5a ). To investigate whether disruption of pre-existing CAR affects CoxB3 infections, we either treated HL-1 cells with the trypsin-involving experimental procedure described above, or omitted the trypsinization step after AdshCAR4 m transduction. The titers of CoxB3 progeny virus generated 5 and 6 days after CoxB3 infection were reduced strongly by about 97% in AdshCAR4 m -transduced cells, irrespective of whether membrane-associated CAR was disrupted by trypsinization or not (Figure 5b ). These experiments indicate that AdshCAR4 m inhibits CoxB3 replication in HL-1 cells with high efficacy. Moreover, proteolysis of membrane-associated CAR apparently does not affect CoxB3 infection.
Inhibition of adenovirus infections of HL-1 cells by AdshCAR4 m
CAR is also involved in adenovirus infection as an attachment receptor. To investigate the long-term efficacy of AdshCAR4 m with respect to the inhibition of were infected with adenovirus. Its uptake was reduced by 85 and 92%, respectively, on days 6 and 8 after AdshCAR2 m transduction, whereas no effect was seen on day 3 ( Figure 7c ).
Discussion
CoxB3 and adenoviruses are common agents of acute myocarditis and inflammatory cardiomyopathy.
1,3
Although interferon-b treatment has the potential to eliminate cardiotropic viruses and to improve heart function in patients with myocardial persistence of viral genomes, 31 no specific treatment against CoxB3 and adenovirus infections is available to date. With respect to antiviral therapy, RNAi is a promising new technology. Its therapeutic potential against viral infections has been demonstrated in multiple in vitro and in vivo 5-7,13-15 Despite encouraging results, however, several reports have revealed a fundamental general problem of siRNA-based antiviral therapy. Owing to the requirement for strict sequence-specificity between therapeutic siRNA and target mRNA, even single point mutations in the viral target sequence may result in the rapid selection of escape mutants during persistent viral infections. [17] [18] [19] In this study, we show that inhibition of CoxB3 and adenovirus infections is possible via silencing of the CAR receptor by means of vector-generated CAR-shRNA. This strategy is an attractive alternative to siRNA-based silencing of virus-encoded gene, because it drastically reduces the probability of escape mutant development. 22 In contrast to previous work, 15 our investigations were carried out in myocardial cells representing the actual targets for CoxB3 and adenovirus infections in acute myocarditis and inflammatory cardiomyopathy. 32 Treatment of HL-1 cells with the shCAR vector led to efficient and stable removal of mCAR protein from the cell surface, and consequently, to significant inhibition of CoxB3 and adenovirus infection of these cells. Remarkably, adenovirus internalization was reduced by only E75% despite the near-complete silencing of mCAR expression, whereas CoxB3 infection was inhibited by up to 97%. In contrast, CAR silencing in PNCMs resulted in strong inhibition of both adenovirus and CoxB3 infections (by 92 and 90%, respectively). Adenovirus binding to cells is not exclusively mediated by CAR. Type 2 and 5 adenoviruses use CAR to attach to the cell surface, 33 whereas its internalization occurs through a v b 1 , a v b 3 and a v b 5 integrin. 29, 34, 35 Others have shown that heparan sulfate glycosaminoglycans and major histocompatibility complex class I molecules may also be involved in the binding of adenoviruses 2 and 5. 36, 37 Moreover, the expression of receptors involved in adenovirus infections is highly variable between different cell types and tissues. 38 Thus, variable receptor expression levels and interactions of adenoviruses with cell type-specifically expressed alternative receptors are the most likely explanation for the failure of complete CAR silencing to achieve efficient blockade of adenovirus infection in HL-1 cells. To enhance efficacy in inhibition of adenovirus infection via the anti-receptor approach, it seems to be necessary to simultaneously inhibit CAR and its co-receptors.
In contrast to the anti-adenovirus experiments, the anti-CAR approach was efficient with respect to CoxB3 in both HL-1 cells and PNCMs. The magnitude of inhibition of CoxB3 infection correlated well with the vector-induced ablation of mCAR from the cell surface and emphasizes the key role of CAR in CoxB3 infections of cardiac cells. The molecular reason for the differences of anti-CAR treatment in adenovirus versus CoxB3 infections may be the unique role played by CAR during CoxB3 infection as it induces conformational changes in the virus capsid that are essential for CoxB3 entry into the target cell. 27 The high efficacy of the shCAR vector against this virus indicates that CAR silencing is a promising therapeutic approach against CoxB3 infections of the myocardium. Previous studies have shown a similar degree of inhibition when using siRNAs directed against CoxB3 viral genomic RNA or its RNA intermediate. 14, 15, 39 Combination of direct antiviral approaches, which are prone to escape mutant development with the current anti-receptor strategy, is likely to further increase the efficacy of RNAi-based antiviral therapy.
Recently, it has been shown that silencing of CAR by chemically synthesized siRNA inhibited CoxB3 infection in human cells of non-cardiac origin. 27 However, this approach decreased virus titers by only E60% 15 which is markedly less than in the present study employing AdVgenerated shCARs. This difference should be the result of high transduction efficacy of AdVs and the prolonged high-level expression of the shCAR. A bottleneck of chemically synthesized siRNAs is its transient silencing activity of E3 days in cardiac cells. 28 Viral vectors expressing shRNAs, however, enable long-term silencing of target genes in cells of cardiac origin 40 and allow efficient delivery of transgenic sequences to the heart. 41, 42 Among the currently available viral vectors, pseudotyped AAV9 vectors appear to be most promising for cardiac gene therapy as they allow highly efficient Antiviral efficacy of CAR silencing by RNA interference H Fechner et al targeted transduction of the heart by way of simple intravenous injection. 43, 44 CAR is a cell adhesion protein mediating homotypic 45, 46 and heterotypic 47 intercellular interactions. It is a component of specialized intercellular junctions including epithelial tight junctions, 45 neuro-muscular junctions 48 and myocardial intercalated discs. 49 We found it to be localized exclusively at cell-to-cell contact sites between HL-1 cells, possibly as a consequence of cell membrane-associated CAR stabilization through homotypic (CAR-CAR) or heterotypic (CAR-protein) intercellular protein interactions. In contrast to previous CAR silencing attempts using synthetic siRNAs, the newly developed viral vectors AdshCAR4 m and AdshCAR2 m achieved near complete and stable knockout of CAR. This was an essential prerequisite to reveal significantly different kinetics of CAR protein ablation in different cell types, in particular, an unexpectedly high stability of CAR in primary cells versus a stable cell line. These data may be explained by cell type-specific CAR protein kinetics, but differential CAR-mRNA stability or CAR-shRNA processing through the cellular micro-RNA/shRNA machinery also need to be taken into account. The delayed downregulation of CAR following vector-mediated CAR-shRNA delivery in primary cardiomyocytes is relevant for in vivo investigations because the time lag between vector application and CAR silencing needs to be considered in the development of antiviral therapy protocols.
An important concern associated with downregulation of a cellular receptor molecule for antiviral therapy are the possible side effects resulting from ablation of the normal cellular functions of the receptor. During organogenesis, CAR is highly expressed in the heart, but rapidly downregulated post partum. 50 In a recently published genomic mouse knockout model, cardiomyocyte-specific CAR deletion resulted in severe cardiac anomalies and death between days 11.5 and 13.5 of embryonal development. 51, 52 If the CAR gene became ablated late in embryonic development, however, the CAR-deficient animals survived into adulthood and had no evident cardiac anomalies. 51 This finding suggests that CAR silencing by RNAi, as employed in our study, should be well tolerable over considerable periods of time, during which virus migration and spreading were efficiently inhibited. Furthermore, treatment of HL-1 cells with AdV-generated shCAR revealed no side effects as we found no changes in cell growth, cell morphology or F-actin cytoskeleton protein expression (not shown). As CAR is a component of tight junctions and may play a permanent role in tissue function of several organs, further experiments have to examine if CAR knockdown by RNAi has no side effects in vivo even over prolonged treatment times.
In summary, high efficacy of CAR gene silencing by shRNAs in cardiac-derived cells was observed against CoxB3, whereas cell type-dependent results were obtained against adenovirus. In contrast to previous silencing attempts using siRNAs or shRNA-plasmid, the newly developed shRNA vectors were able to achieve nearly complete and stable knockout of CAR transcription. This, in turn, revealed significantly different responses of cellular CAR protein to CAR-shRNA treatment, which need to be considered as important determinants of this new antiviral approach in vivo.
Materials and methods
Cell cultures
The HL-1 cell line, a cardiac muscle cell line established from an AT-1 mouse atrial cardiomyocyte tumor lineage, was a kind gift from William C Claycomb. The cells were maintained in Claycomb medium supplemented with 10% fetal calf serum (FCS) (JRH Bioscience, Lenexa, USA), 1% each of penicillin and streptomycin, 0.1 mM norepinephrine (Sigma, Mü nchen, Germany) and 2 mM L-glutamine (Invitrogen, Karlsruhe, Germany). HeLa (human cervical carcinoma) cells, HEK293 (human embryonal kidney) and HEK293T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Gibco BRL, Karlsruhe, Germany) supplemented with 10% FCS and 1% penicillin/streptomycin. PNCMs were generated and maintained as described previously. 40 
Construction of expression plasmids
For each mCAR-shRNA, four short oligonucleotides that cover antisense, loop and sense sequence of the shRNA were synthesized (Oligoservice, Berlin, Germany). The target sequence of shCAR2 m and shCAR3 m encompassed 19 nucleotides, and that of shCAR4 m 21 nucleotides (see Figure 1 ). The forward and reverse oligos were phosphorylated by T4 polynucleotide kinase (New England BioLabs, Frankfurt, Germany), annealed and cloned into HindIII/BamHI-digested pSilencerTM 2.1-U6 neo (Ambion, Austin, TX, USA). The shRNA expression cassettes were then cloned into pAdshPLB r 40 via EcoRI/ HindIII to yield the plasmids pAdshCAR2 m , pAdsh-CAR3 m and pAdshCAR4 m .
For the generation of the mCAR1 expression plasmid pAdmCAR1, total RNA was first isolated from HL-1 cells and reverse-transcribed by the use of SuperScriptII reverse transcriptase (Invitrogen). The mCAR1-cDNA was then amplified using the primer pair MCAR105s (5 0 -CGGCAGCYACCATGGCGC-3 0 ) and HCAR-1157 (5 0 -CTATACTATAGACCCATCCTTG-3 0 ) in a 35-cycle PCR with Pwo polymerase (Roche, Mannheim, Germany), and the resulting fragment was then cloned in the pCR2.1-TOPO vector (Invitrogen). An EcoRI fragment containing mCAR1-cDNA was excised and inserted into the shuttle plasmid pZS2. 53 For generation of the recombinant mCAR2 expression plasmid pAdm-CAR2, the mCAR2 cDNA was excised from pCR3.1-mCAR2 with HindIII/PmeI and cloned into pZS2 via SmaI/HindIII. Correctness of all plasmids was proven by sequencing on an ABI 310 genetic analyzer (Applied Biosystems, Foster city CA, USA).
Development of AdVs
The adenoviral shuttle plasmids pAdshCAR4 m and pAdshCAR2 m were linearized with SpeI and ligated to the 5 0 'long arm' of the XbaI-digested E1 À E3 À adenovirus mutant RR5, transfected in HEK293 cells and propagated as described. 54 This resulted in the AdVs AdshCAR2 m , AdshCAR4 m and AdshPLB r . An additional shGFP expressing AdV (AdshGFP) containing an siRNA target sequence (5 0 -GGTTATGTACAGGAACGCA-3 0 ) directed against GFP was generated in the same way as AdshCAR4 m and AdshCAR2 m . The AdVs Ad5CMVGFP, Ad5CMVluc 38 and AdshPLB r 40 have been described. All AdVs were tested for possible RCA contamination by Antiviral efficacy of CAR silencing by RNA interference H Fechner et al PCR as described. 53 Virus titers were determined by standard plaque assays on HEK293 cells.
Plasmid transfections
Plasmid transfections were carried out by calcium phosphate precipitation. Cells were seeded in six-well plates at a density of 5 Â 10 5 cells/well and transfected with 1 mg of each plasmid/well in 250 ml 2 Â HBS buffer, pH 7.1 and 250 ml 0.25 M CaCl 2 in the presence of DMEM containing 10% FCS. After 24 h, cells were washed three times with phosphate-buffered solution (PBS) and supplied with fresh growth medium.
Northern blots
Total RNA was isolated with TRIzol Reagent (Invitrogen) following the manufacturer's instruction. Ten micrograms of isolated RNA was electrophoretically separated on 1% formaldehyde agarose gels. After transfer to a Hybond N nylon membrane (Amersham, Buckinghamshire, UK), the membranes were hybridized with a single-stranded (ss) antisense mCAR1-specific DNA probe using the mCAR1-cDNA excised from pAdm-CAR1 as template. Rehybridization to control for equal DNA loading was carried out with an ss-antisense b-actin-specific DNA probe as described, 55 ]dCTP in a PCR-like reaction was described. 38 Hybridized filters were exposed to Kodak Biomax MS film (Integra Biosciences, Fernwald, Germany) and hybridization signal intensity was then determined by phosphoimaging in a Fuji Film BAS-1500 imager (Fuji Photo Film, Dusseldorf, Germany).
Flow cytometry
To determine the fraction of cells transduced by an AdV, HL-1 cells were seeded in a six-well plate at a density of 4 Â 10 5 cells/well. After 24 h, the cells were transduced with different MOI of adenoviral GFP marker vector (Ad5CMVGFP). 38 Flow cytometry was performed 48 h later on a FACS Calibur with CellQuest software (Becton Dickinson, Franklin Lakes, NJ, USA).
Quantitative real-time reverse transcription-PCR
Total RNA from HL-1 cells was isolated with RNAzol. Four micrograms of RNA was incubated with peqGOLD DNaseI (Peqlab, Erlangen, Germany) at 371C for 30 min. The reaction was stopped by addition of 2.5 ml of 25 mM ethylenediaminetetraacetic acid (EDTA) and heating for 15 min to 651C. RNA was reverse-transcribed using the High Capacity cDNA Archive Kit (Applied Biosystems) according to the manufacturer's instruction. For the quantification of gene expression, quantitative PCR assay was performed on a Mastercycler ep Gradient S (Eppendorf) with TaqMan Universal Master Mix UNG (Applied Biosystems) using the standard conditions determined by the company. After AmpliTaqGold activation for 10 min at 951C, 40 cycles were run at a denaturing temperature of 951C (15 s) and an annealing/ extension temperature of 601C (1 min). A unique combination of forward and reverse primers and fluorescent MGB probes designed by the company was used for the mCAR1 target gene, and the HPRT and GAPDH housekeeping genes, respectively, which were used for normalization. cDNA corresponding to 50 ng of RNA was used per 20 ml reaction and each reaction was performed in triplicate. The level of expression was calculated on the basis of the PCR cycle number (C t ) at which the exponential growth in fluorescence from the probe passes a certain threshold value. Relative expression (DC t ) was determined by the difference in the C t values for the target gene after normalization to RNA input level, using HPRT C t values. Relative quantification was determined by standard 2 ðÀDCtÞ calculation in percent.
Assessment of cellular shCAR4 expression levels
Semiquantitative analysis of shCAR4 m expression included two steps: an RT reaction containing 50 ng/ml total RNA samples, 50 nM shCAR4 stem-loop RT primer (5 0 -GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCA CTGGATACGACTTCCAA-3 0 ), 1 Â RT buffer (Applied Biosystems), 0.25 mM each of dNTP, 3.33 U/ml MultiScribe reverse transcriptase (Applied Biosystems) and 0.25 U/ml RNAse inhibitor (Peqlab). The 7.5 ml reactions were incubated for 30 min at 161C, 30 min at 421C, 5 min at 851C and then held at 41C. The 20 ml PCR reactions included 1 ml of RT product, 1 Â Gene Amp PCR buffer and 1.25 U AmpliTaq DNA polymerase (Roche), 0.25 mM each of dNTP and 1.5 mM forward primer (5 0 -GCGGCGGATCGGAAGAGATT-3 0 ) and reverse primer (5 0 -GTGCAGGGTCCGAGGT-3 0 ) specific for shCAR4 mcDNA. The reactions were incubated in a Gene Amp PCR System 9700 (Applied Biosystems) at 951C for 4 min, followed by 30 cycles at 951C for 15 s and 601C for 1 min and analyzed by gel electrophoresis. Alternatively, shCAR4 m quantification was carried out by real-time PCR. The TaqMan reactions contained 1 Â TaqMan Universal PCR Master Mix (Applied Biosystems), 1 ml of RT product, 200 nM forward primer, 200 nM reverse primer and Sybr Green (Invitrogen) at 1:10 000. The reactions were incubated in a 96-well plate at 951C for 10 min, followed by 40 cycles at 951C for 15 s and 601C for 1 min, and run in triplicate. The threshold cycle (C t ) is defined as the fractional cycle number at which the fluorescence passes the fixed threshold. The relative shCAR4 m expression was calculated by the formula y ¼ 2 ðC t MOI 5ÀC t MOI xÞ .
Western blots
Cells were solubilized in general lysis buffer (20 mM Tris, pH 8, 10 mM NaCl, 0.5% (v/v) Triton X-100, 5 mM EDTA, 3 mM MgCl 2 ). After boiling of the lysate at 951C for 5 min, proteins were separated on NuPAGE 4-12% BisTris gels (Invitrogen) under denaturing and reducing conditions and transferred onto a PVDF membrane (Bio-Rad, Hercules, CA, USA). Subsequently, the membrane was incubated with anti-CAR polyclonal antibody H-300 1:200 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h in dry milk. Secondary swine -anti-rabbit antibodies conjugated with peroxidase (DAKO, Hamburg, Germany) were used at 1:10 000 dilution. Detection by chemiluminescence was achieved by using an enhanced chemiluminescence system (Amersham Biosciences).
Indirect immunofluorescence
HL-1 cells were fixed with 1 ml of Tris-buffered solution (TBS) containing 4% formaldehyde and permeabilized by 0.5% Triton X-100. After blocking in TBS buffer with Antiviral efficacy of CAR silencing by RNA interference H Fechner et al 5% FCS and 0.1% Triton X-100, cells were incubated with anti-mCAR1 rabbit polyclonal antibody RP-291 56 diluted 1:100 in blocking solution for 1 h. After extensive rinsing, the cells were incubated with a biotin-labeled donkey-anti-rabbit secondary antibody (Dianova, Hamburg, Germany) at a dilution of 1:400 for 1 h. Cells were subsequently incubated with Cy3-conjugated streptavidin (Dianova) (dilution 1:500) for 30 min and nuclei were stained with 4,6-diamidino-2-phenylindole (0.5 mg/ml) (Sigma). After covering with Fluoromount GTM (Southern Biotechnology, Birmingham, AL, USA), images were taken by using an Olympus BX60 immunofluorescence microscope.
Luciferase assays
Luciferase assays were performed using the luciferase reporter gene assay kit (Roche) following the manufacturer's instructions. Briefly, cells were washed twice with PBS buffer and lysed directly by adding 250 ml of cell lysis reagent and incubating for 15 min at room temperature. Cell debris was pelleted in a microfuge at maximum speed for 15 s and 10 ml of the supernatant was then transferred to a 5-ml tube (Sarstedt, Nü rnberg, Germany). Luciferase substrate (50 ml) was added and the luciferase activity was immediately measured in a Lumat LB 9501 luminometer (Berthold, Bad wildbad, Germany).
Virus plaque assays
HeLa cells were cultured in six-well cell culture plates as confluent monolayers at a density of 1.2 Â 10 6 cells/well and incubated at 371C in Eagle's MEM (minimal essential medium) with 5% (v/v) FCS under 5% (v/v) CO 2 . After 24 h, cells were overlaid with 1 ml of diluted supernatant from HL-1 cells, which were treated by three freeze/ thaw cycles to release intracellular CoxB3 virus. The HeLa cell culture was then incubated at 371C for 30 min, the supernatant removed and the cells overlaid with 2 ml agar containing Eagle's MEM. Three days later, cells were stained with 0.025% (w/v) neutral red. The virus titer was determined by plaque counting 3 h after staining. Mean and standard deviation were calculated from two independent experiments, each performed in duplicate.
Statistical analysis
To test for statistical significance, Student's t-test was applied. A value of Po0.05 was considered statistically significant.
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